outbreak
middl
east
respiratori
syndrom
coronaviru
merscov
total
six
differ
commerci
merscov
rna
detect
kit
base
realtim
reversetranscript
polymeras
chain
reaction
rrtpcr
avail
korea
powerchek
mer
realtim
pcr
kogen
biotech
seoul
korea
diaplexq
mer
viru
detect
solgent
daejeon
korea
anyplex
ii
merscov
upe
realtim
detect
kit
seegen
seoul
korea
compris
two
step
singl
gene
target
region
upstream
envelop
gene
upe
screen
multipl
gene
target
upe
open
read
frame
confirm
accupow
merscov
real
time
rtpcr
bioneer
daejeon
korea
lightmix
molecular
dx
merscov
roch
molecular
diagnost
basel
switzerland
ultrafast
labchip
merscov
realtim
pcr
kit
nanobiosi
seoul
korea
use
one
step
simultan
detect
upe
use
two
singl
genetarget
reagent
none
kit
approv
diagnost
use
howev
urgent
introduc
clinic
laboratori
june
time
diagnosi
merscov
infect
essenti
nationwid
merscov
outbreak
korea
unit
state
center
diseas
control
prevent
us
cdc
provid
guidelin
molecular
diagnosi
merscov
sinc
june
us
cdc
made
novel
coronaviru
rrtpcr
assay
avail
free
charg
emerg
use
author
although
least
three
commerci
rrtpcr
assay
merscov
detect
avail
altona
diagnost
fast
track
diagnost
primerdesign
http
wwwgenesigcom
outbreak
korea
realstar
merscov
altona
diagnost
hamburg
germani
approv
vitro
diagnosi
merscov
ce
author
emerg
use
unit
state
therefor
six
commerci
kit
evalu
studi
valid
diagnost
use
studi
design
analyt
clinic
valid
six
abovement
commerci
mer
cov
rna
detect
kit
juli
kit
valid
use
equip
recommend
manufactur
tabl
determin
analyt
sensit
limit
detect
lod
probabl
valu
determin
use
upe
rna
transcript
suppli
institut
virolog
univers
bonn
medic
centr
origin
concentr
rna
transcript
dilut
six
concentr
step
copiesreact
kit
test
use
sampl
rna
eluat
per
reaction
nanobiosi
kit
use
sampl
per
reaction
higher
concentr
ad
lod
valid
concentr
test
use
replic
except
powerchek
replic
use
probit
regress
analysi
r
studio
r
studio
inc
http
wwwrstudiocom
perform
determin
cutoff
valu
powerchek
accupow
lightmix
ultrafast
labchip
kit
use
primer
probe
whorecommend
rrtpcr
assay
primer
probe
use
diaplexq
anyplex
kit
modifi
whorecommend
rrtpcr
assay
cover
almost
region
upe
person
commun
confidenti
sequenc
howev
anyplex
kit
valid
upe
oligonucleotidebind
site
beyond
span
rna
transcript
use
studi
evalu
analyt
clinic
specif
kit
respiratori
virusposit
nasopharyng
swab
use
determin
crossreact
human
rna
respiratori
virus
includ
human
coronavirus
use
anyplex
ii
kit
seegen
duplic
specimen
prepar
specimen
confirm
posit
singl
speci
follow
virus
influenza
viru
influenza
viru
b
human
parainfluenza
viru
human
parainfluenza
viru
human
parainfluenza
viru
respiratori
syncyti
viru
respiratori
syncyti
viru
b
human
adenoviru
human
bocaviru
human
metapneumoviru
human
rhinoviru
human
coronaviru
human
coronaviru
human
coronaviru
evalu
clinic
sensit
assay
specimen
lower
respiratori
tract
includ
known
posit
specimen
obtain
five
institut
rna
eluat
nine
specimen
remain
initi
clinic
merscov
rrtpcr
test
use
follow
storag
month
institut
nine
specimen
manual
prepar
laboratori
without
pretreat
found
inadequ
evalu
clinic
sensit
owe
extrem
high
level
pcr
inhibit
therefor
first
nine
specimen
use
evalu
clinic
sensit
nine
specimen
high
inhibit
use
evalu
effect
pcr
inhibit
posit
result
addit
determin
number
posit
neg
cycl
threshold
ct
valu
target
gene
intern
control
analyz
lod
upe
vari
copiesreact
vari
copiesreact
fig
accord
probit
regress
analysi
confid
interv
ci
upe
found
overlap
among
test
kit
except
powerchek
kit
fig
lod
upe
use
singl
multipl
genetarget
format
kit
log
copiesreact
powerchek
kit
log
copiesreact
diaplexq
kit
fig
lod
upe
log
copiesreact
anyplex
kit
ci
valu
could
calcul
posit
reaction
log
copyreact
replic
specimen
posit
log
copiesreact
contrast
although
lod
upe
use
lightmix
kit
log
copiesreact
log
copiesreact
respect
trail
posit
observ
much
lower
concentr
lod
fig
lod
upe
three
differ
kit
accupow
light
mix
ultrafast
kit
log
copiesreact
less
sensit
three
differ
kit
howev
differ
signific
fig
lod
vari
log
except
powerchek
kit
consider
lower
log
copiesreact
fig
none
kit
test
studi
show
crossreact
respiratori
virus
base
valid
test
includ
specif
panel
nine
clinic
specimen
clinic
sensit
detect
upe
ci
studi
kit
specif
ci
posit
sampl
show
wide
rang
ct
valu
valu
result
kit
tabl
ct
valu
intern
control
vari
powerchek
diaplexq
anyplex
accupow
lightmix
ultrafast
vari
tabl
test
diaplexq
kit
detect
five
posit
specimen
upe
result
ultrafast
kit
avail
three
posit
specimen
one
capillari
pcr
chamber
hold
specimen
leak
effect
pcr
inhibit
determin
test
nine
high
inhibit
specimen
reveal
six
known
posit
specimen
found
neg
invalid
kit
tabl
ct
valu
intern
control
specimen
high
extend
beyond
total
amplif
cycl
therefor
fals
neg
result
elimin
owe
intern
control
failur
except
powerchek
accupow
kit
accupow
kit
mean
intern
control
ct
valu
high
inhibit
specimen
consider
prolong
compar
sensit
test
specimen
howev
establish
cutoff
point
indic
pcr
inhibit
accept
pcr
reaction
hand
ct
valu
sensit
test
specimen
high
inhibit
specimen
use
powerchek
kit
significantli
differ
respect
lightmix
kit
produc
two
uncertain
result
known
posit
specimen
one
uncertain
result
known
neg
specimen
tabl
posit
result
detect
kit
among
four
neg
specimen
includ
sensit
test
high
inhibit
panel
tabl
lod
upe
rrtpcr
kit
analyz
rna
transcript
use
evalu
realstar
merscov
altona
diagnost
kit
thu
far
approv
diagnosi
compar
analyt
sensit
assay
system
import
use
consist
evalu
condit
moreov
qualiti
sourc
materi
critic
often
difficult
find
traceabl
sourc
materi
molecular
diagnosi
viral
infect
intern
standard
establish
date
realstar
merscov
target
genebind
site
upe
use
studi
kit
base
oligonucleotid
sequenc
whorecommend
primer
probe
upe
target
site
locat
within
rna
transcript
use
studi
whole
genom
sequenc
merscov
isol
obtain
korean
outbreak
determin
korea
nation
institut
health
seoul
nation
univers
guangdong
provinci
center
diseas
control
prevent
sequenc
close
cluster
strain
isol
spring
outbreak
riyadh
saudi
arabia
therefor
primer
probe
use
studi
like
affect
sequenc
variat
merscov
strain
circul
outbreak
rna
transcript
use
assess
analyt
sensit
detect
upe
expect
target
mismatch
primer
probe
use
studi
therefor
lod
kit
analyz
use
ident
sourc
materi
data
compar
among
variou
kit
well
data
previou
evalu
realstar
merscov
lod
upe
kit
assess
studi
indic
approxim
lower
sensit
previous
report
cutoff
valu
copiesreact
realstar
merscov
overal
sensit
detect
upe
kit
evalu
herein
consist
lower
realstar
merscov
kit
fig
lod
use
powerchek
duplex
kit
similar
realstar
kit
copiesreact
use
realstar
merscov
kit
comparison
copiesreact
use
powerchek
kit
therefor
lower
sensit
kit
evalu
comparison
realstar
merscov
could
attribut
perform
rather
instabl
sourc
materi
comparison
realstar
merscov
kit
analyz
herein
room
improv
sensit
except
test
powerchek
kit
unlik
test
kit
lightmix
kit
demonstr
markedli
trail
tendenc
yield
posit
result
much
lower
concentr
lod
uncertain
result
even
knownneg
specimen
fig
find
suggest
effort
increas
sensit
may
result
uncertainti
therefor
neg
impact
specif
previou
studi
clinic
sensit
realstar
merscov
produc
four
discrep
result
among
specimen
three
specimen
oral
nasal
urin
specimen
show
high
ct
valu
use
realstar
kit
use
comparison
assay
vice
versa
one
nasal
specimen
could
result
realstar
merscov
higher
sensit
lower
specif
assay
use
kit
test
studi
lod
upe
use
multipl
genetarget
format
compar
obtain
use
singl
genetarget
format
fig
therefor
implement
approach
includ
perform
first
screen
step
singl
genetarget
format
benefici
term
sensit
present
studi
lod
analyz
use
dilut
seri
dilut
consid
within
physiolog
variat
signific
viral
kinet
howev
limit
dilut
scale
wide
estim
ci
valu
anyplex
kit
fig
estim
lod
probit
regress
analysi
seem
less
appropri
lightmix
kit
trail
tendenc
much
lower
concentr
lod
use
diaplexq
kit
measur
low
sensit
kit
detect
clinic
specimen
consist
previou
report
test
less
sensit
test
upe
crossreact
observ
respiratori
virus
includ
human
coronaviru
assay
includ
studi
find
consist
previou
evalu
use
primer
probe
recommend
therefor
assay
system
demonstr
adequ
specif
clinic
sensit
kit
tabl
sensit
test
panel
compris
variou
posit
specimen
wide
rang
ct
valu
high
sensit
valid
diagnost
perform
merscov
infect
particularli
sputum
specimen
although
number
posit
specimen
small
one
strength
present
studi
determin
effect
pcr
inhibit
clinic
sensit
import
intern
control
tabl
intern
control
powerchek
kit
affect
inhibit
could
powerchek
kit
use
less
sensit
intern
control
intrins
human
cell
although
pcr
effici
kit
also
less
affect
posit
rate
kit
test
high
inhibit
panel
correl
analyt
sensit
powerchek
detect
knownposit
specimen
base
find
clear
clinic
sensit
significantli
affect
presenc
pcr
inhibitor
analyt
sensit
may
affect
pcr
inhibitionpron
specimen
sputum
specimen
therefor
optim
pretreat
rna
extract
procedur
necessari
improv
sensit
merscov
molecular
diagnost
especi
test
sputum
specimen
noteworthi
limit
studi
includ
number
specimen
use
test
clinic
sensit
rel
small
reproduc
assay
result
valid
effect
inhibit
qualit
estim
conclus
commerci
kit
evalu
studi
demonstr
variabl
analyt
sensit
howev
overal
clinic
sensit
specif
suffici
diagnos
merscov
infect
perform
individu
kit
could
improv
term
analyt
sensit
identif
pcr
inhibit
use
appropri
intern
control
essenti
